Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Kiniksa Pharmaceuticals International (KNSA) Return on Capital Employed (2021 - 2025)

Kiniksa Pharmaceuticals International's Return on Capital Employed history spans 5 years, with the latest figure at 0.13% for Q4 2025.

  • For Q4 2025, Return on Capital Employed rose 23.0% year-over-year to 0.13%; the TTM value through Dec 2025 reached 0.13%, up 23.0%, while the annual FY2025 figure was 0.14%, 25.0% up from the prior year.
  • Return on Capital Employed reached 0.13% in Q4 2025 per KNSA's latest filing, up from 0.07% in the prior quarter.
  • In the past five years, Return on Capital Employed ranged from a high of 0.13% in Q4 2025 to a low of 0.79% in Q4 2021.
  • Average Return on Capital Employed over 5 years is 0.13%, with a median of 0.06% recorded in 2023.
  • Peak YoY movement for Return on Capital Employed: skyrocketed 81bps in 2022, then dropped -15bps in 2024.
  • A 5-year view of Return on Capital Employed shows it stood at 0.79% in 2021, then soared by 103bps to 0.02% in 2022, then crashed by -341bps to 0.06% in 2023, then crashed by -71bps to 0.1% in 2024, then skyrocketed by 232bps to 0.13% in 2025.
  • Per Business Quant, the three most recent readings for KNSA's Return on Capital Employed are 0.13% (Q4 2025), 0.07% (Q3 2025), and 0.01% (Q2 2025).